1. Sellers, T. A. (1997). Genetic factors in the pathogenesis of breast cancer: their role and relative importance. The Journal of nutrition, 127(5), 929S-932S.
2. Kolstad, H. A. (2008). Nightshift work and risk of breast cancer and other cancers—a critical review of the epidemiologic evidence. Scandinavian journal of work, environment & health, 5-22.
3. Davies, L., & Welch, H. G. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama, 295(18), 2164-2167.
4. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 100(7), 3983-3988.
5. Ronckers, C. M., Erdmann, C. A., & Land, C. E. (2004). Radiation and breast cancer: a review of current evidence. Breast Cancer Research, 7(1), 21.
6. Ingvarsson, S. (2003). Molecular genetics of breast cancer. International Journal of Human Genetics, 3(2), 69-78.
7. Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 9(7), 463.
8. Pal, S. K., & Mortimer, J. (2009). Triple-negative breast cancer: novel therapies and new directions. Maturitas, 63(4), 269-274.
9. Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin Jr, W., Ferraro, M., Burrows, E., ... & Winer, E. P. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Journal of Clinical Oncology, 26(15_suppl), 1009-1009.
10. Cai, Y., Yu, X., Hu, S., & Yu, J. (2009). A brief review on the mechanisms of miRNA regulation. Genomics, proteomics & bioinformatics, 7(4), 147-154.
11. Farazi, T. A., Spitzer, J. I., Morozov, P., & Tuschl, T. (2011). miRNAs in human cancer. The Journal of pathology, 223(2), 102-115.
12. Manikandan, J., Aarthi, J. J., Kumar, S. D., & Pushparaj, P. N. (2008). Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation, 2(8), 330.
13. Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010). Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer research, 0008-5472.
14. Tao, Z., Shi, A., Lu, C., Song, T., Zhang, Z., & Zhao, J. (2015). Breast cancer: epidemiology and etiology. Cell biochemistry and biophysics, 72(2), 333-338.
15. Roskoski Jr, R. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological research, 79, 34-74.
16. Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 1117-1134.
17. Rimawi, M. F., Shetty, P. B., Weiss, H. L., Schiff, R., Osborne, C. K., Chamness, G. C., & Elledge, R. M. (2010). Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer: Interdisciplinary International Journal of the American Cancer Society, 116(5), 1234-1242.
18. Xu, B., Tao, T., Wang, Y., Fang, F., Huang, Y., Chen, S & Chen, M. (2016). hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR. Tumor Biology, 37(10), 14141-14151.
19. Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. (2013). Delivering the promise of miRNA cancer therapeutics. Drug discovery today, 18(5-6), 282-289.
20. Guo, J., Gong, G., & Zhang, B. (2018). miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer. Scientific reports, 8(1), 2073.
21. Jin, C., Rajabi, H., & Kufe, D. (2010). miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. International journal of oncology, 37(1), 61-69.
